PROPINE
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROPINE is a small-molecule ophthalmic solution approved in 1980 for treatment of glaucoma and ocular hypertension. The product is administered as eye drops and works through adrenergic mechanisms to reduce intraocular pressure. It represents a legacy therapy in the ophthalmology space with four decades of clinical use.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), indicating a defensive portfolio strategy and potentially smaller commercial team focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PROPINE offers limited career growth potential given the product's LOE-approaching status and zero linked job openings. Roles available are primarily defensive and focused on maintaining market share and managing generic transition rather than launching or growing the brand.
Brand ManagerField Sales Representative
Worked on PROPINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.